Development of protein degradation inducers of oncogenic BCR‐ABL protein by conjugation of ABL kinase inhibitors and IAP ligands

Chromosomal translocation occurs in some cancer cells, which results in the expression of aberrant oncogenic fusion proteins that include BCR‐ABL in chronic myelogenous leukemia (CML). Inhibitors of ABL tyrosine kinase, such as imatinib and dasatinib, exhibit remarkable therapeutic effects, although...

Descripción completa

Detalles Bibliográficos
Autores principales: Shibata, Norihito, Miyamoto, Naoki, Nagai, Katsunori, Shimokawa, Kenichiro, Sameshima, Tomoya, Ohoka, Nobumichi, Hattori, Takayuki, Imaeda, Yasuhiro, Nara, Hiroshi, Cho, Nobuo, Naito, Mikihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5543464/
https://www.ncbi.nlm.nih.gov/pubmed/28556300
http://dx.doi.org/10.1111/cas.13284

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5543464/
https://www.ncbi.nlm.nih.gov/pubmed/28556300
http://dx.doi.org/10.1111/cas.13284

Ejemplares similares